|1.||Wei, Er-Qing: 8 articles (04/2011 - 10/2002)|
|2.||Matsuse, Hiroto: 6 articles (02/2014 - 05/2004)|
|3.||Kohno, Shigeru: 6 articles (02/2014 - 05/2004)|
|4.||Zhang, Wei-Ping: 6 articles (04/2011 - 10/2002)|
|5.||Kohno, S: 6 articles (07/2005 - 08/2001)|
|6.||Kawano, Tetsuya: 5 articles (08/2012 - 05/2004)|
|7.||Fukushima, Chizu: 5 articles (08/2012 - 05/2004)|
|8.||Tomari, Shinya: 5 articles (08/2012 - 05/2004)|
|9.||Fang, San-Hua: 5 articles (04/2011 - 08/2005)|
|10.||Okubo, Kimihiro: 4 articles (11/2012 - 12/2008)|
|1.||Asthma (Bronchial Asthma)
08/01/2001 - "Protocol 2: Pranlukast was effective in group I and II, but not in group III. In groups I and II, pranlukast tended to be more effective when BDP was introduced within the first year of onset of asthma. "
01/01/2004 - "Long-term treatment with pranlukast is effective for the management of bronchial asthma, particularly in patients with mild to moderate disease. "
06/01/2003 - "Pranlukast is a leukotriene 1 (LT1) receptor antagonist and is effective against bronchial asthma. "
01/01/2003 - "Pranlukast was also effective in patients with mild to severe asthma in a clinical practice setting. "
03/01/2001 - "Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma."
|2.||Seasonal Allergic Rhinitis (Hay Fever)
12/01/2011 - "Pranlukast is effective for prophylactic treatment of pollinosis."
01/01/2009 - "To investigate the efficacy of pranlukast as an early intervention in the control of cedar pollinosis. "
12/01/2011 - "Therefore, this study was performed to determine if pranlukast, a LTRA, met these goals in treatment of pollinosis. "
11/01/2012 - "Noninvasive biological evaluation of response to pranlukast treatment in pediatric patients with Japanese cedar pollinosis."
01/01/2012 - "Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber."
01/01/2009 - "Administering pranlukast immediately before the beginning of cedar pollen dispersion is effective in reducing symptoms of allergic rhinitis throughout the dispersion period."
07/01/2006 - "Early Pranlukast intervention could inhibit nasal mucosal remodeling in allergic rhinitis."
07/01/2006 - "To explore the impact of Pranlukast in nasal mucosal remodeling in experimental allergic rhinitis. "
07/01/2006 - "[Effect of Pranlukast on tissue remodeling in experimental guinea pig allergic rhinitis model]."
12/01/1997 - "A cysLT antagonist, pranlukast, may thus prevent cysLT-mediated symptoms of allergic rhinitis."
|4.||Brain Ischemia (Cerebral Ischemia)
03/01/2006 - "Pranlukast exerts an anti-inflammatory effect on focal cerebral ischemia in the subacute phase that is limited to neutrophil recruitment through the disrupted blood-brain barrier."
03/01/2006 - "Pranlukast reduces neutrophil but not macrophage/microglial accumulation in brain after focal cerebral ischemia in mice."
02/01/2001 - "ONO-1078 showed protective effect on focal cerebral ischemia. "
02/01/2001 - "[Protective effect of ONO-1078, a leukotriene antagonist, on focal cerebral ischemia in mice]."
10/01/2002 - "ONO-1078 slightly improved the neurological deficiency, and dramatically decreased infarct volume and neuron loss which showed a bell shaped dose response effect with highest effect at doses of 0.01-0.3 mg/kg. Enlargement of the ischemic hemisphere and albumin exudation were inhibited at doses of 0.01-1.0 mg/kg. ONO-1078 has the protective effect on focal cerebral ischemia in rats, which is partially attributed to the inhibition of brain edema. "
08/16/2005 - "After ischemia, pranlukast (0.1 mg/kg) was injected intraperitoneally for 5 consecutive days. "
12/01/2003 - "ONO-1078 (0.1, 0.3 mg/kg) and edaravone (10 mg/kg) improved ischemia-induced neurological deficiency and reduced neuron death. "
01/01/2009 - "Thus, we conclude that pranlukast protects endothelial cells from ischemia-like injury via decreasing ROS production and inhibiting NF-kappaB activation, which is leukotriene independent."
01/01/2009 - "Pranlukast attenuates ischemia-like injury in endothelial cells via inhibiting reactive oxygen species production and nuclear factor-kappaB activation."
12/01/2003 - "ONO-1078 (0.03-0.3 mg/kg) and edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-one, a neuroprotective agent) 10 mg/kg were ip injected 30 min before ischemia and 1 h after reperfusion, and once a day afterward. "
|1.||Leukotriene Receptors (Leukotriene Receptor)
|3.||leukotriene D4 receptor (cysteinyl leukotriene receptor)